Patent application number | Description | Published |
20100009382 | METHODS AND COMPOSITIONS FOR DIAGNOSING LUNG CANCER - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ubiquilin 1 markers for cancer. | 01-14-2010 |
20100279301 | METHODS AND COMPOSITIONS FOR DIAGNOSING BLADDER CANCER - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to genes and gene panels as diagnostic markers and clinical targets for bladder cancer. Methods, compositions, and kits for diagnosing, determining, and determining risk of tumor aggressiveness are disclosed. | 11-04-2010 |
20110070652 | PHAGE MICROARRAY PROFILING OF THE HUMORAL RESPONSE TO DISEASE - The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides methods and compositions for phage microarray profiling of cancer (e.g., prostate, lung, or breast cancer). The present invention further provides novel markers useful for the diagnosis, characterization, and treatment of cancers. | 03-24-2011 |
20120142549 | RAF GENE FUSIONS - The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to RAF gene fusions as diagnostic markers and clinical targets for cancer. | 06-07-2012 |
20130267443 | ncRNA AND USES THEREOF - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ncRNAs as diagnostic markers and clinical targets for prostate, lung, breast and pancreatic cancer. | 10-10-2013 |
20140178871 | RECURRENT GENE FUSIONS IN HEMANGIOPERICYTOMA - Provided herein are kits, compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions as diagnostic markers and clinical targets for hemangiopericytoma. | 06-26-2014 |
20140364481 | RNA CHIMERAS IN HUMAN LEUKEMIA AND LYMPHOMA - Provided herein are kits, compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent RNA fusions as diagnostic markers and clinical targets for leukemia. | 12-11-2014 |
20150017637 | RECURRENT GENE FUSIONS IN CANCER - The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to gene fusions as diagnostic markers and clinical targets for cancer. | 01-15-2015 |
20150191795 | RAF GENE FUSIONS - The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to RAF gene fusions as diagnostic markers and clinical targets for cancer. | 07-09-2015 |
20150284802 | ncRNA AND USES THEREOF - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ncRNAs as diagnostic markers and clinical targets for prostate, lung, breast and pancreatic cancer. | 10-08-2015 |
Patent application number | Description | Published |
20080207714 | Diagnosis And Treatment Of Breast Cancer - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to AGTR1 and LBP markers for breast cancer. | 08-28-2008 |
20110034677 | RECURRENT GENE FUSIONS IN PROSTATE CANCER - Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided. | 02-10-2011 |
20120295809 | RECURRENT GENE FUSIONS IN PROSTATE CANCER - Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided. | 11-22-2012 |
20120296070 | RECURRENT GENE FUSIONS IN PROSTATE CANCER - Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided. | 11-22-2012 |
20130040858 | RECURRENT GENE FUSIONS IN PROSTATE CANCER - Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided. | 02-14-2013 |
20140256706 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME - Inhibitors of BET bromodomains and compositions containing the same are disclosed. Methods of using the BET bromodomain inhibitors in the treatment of diseases and conditions wherein inhibition of BET bromodomain provides a benefit, like cancers, also are disclosed. | 09-11-2014 |
20150246923 | 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS - The present disclosure provides substituted 9H-pyrimido[4,5-b]indoles and 5H-pyrido[4,3-b]indoles and related analogs represented by Formula I: | 09-03-2015 |
20160097104 | RECURRENT GENE FUSIONS IN PROSTATE CANCER - Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided. | 04-07-2016 |